Hepatitis Programs

Evaluating and Treating HCV in HIV Positive Patients

Evaluating and Treating HCV in HIV Positive Patients

There has been recent progress in the field of treatmetn for patients with HIV/HCV co-infection.

View on-demand web symposium on the treatment of patients with HIV/HCV co-infection.

This program is available in English, French, and Spanish.

Find out more »

Advances in HCV: Conquering a Scourge

Advances in HCV: Conquering a Scourge

This CME dinner series has been designed to focus on recent advances in chronic hepatitis C (CHC) treatment, especially newly approved therapies. A national thought leader will lead participants through an overview of the updated CHC treatment paradigms and present detailed clinical trial data on newer therapies and strategies that are expected to shape treatment paradigms in the near future.  

Course Director:

Douglas T. Dieterich, MD
Professor of Medicine,
Director of Outpatient Hepatology, Division of Liver Diseases
Director of CME, Department of Medicine,
Mount Sinai School of Medicine
New York, New York

Find out more »

The Improving Landscape of HCV Therapy: The Opportunity to Eliminate a Scrouge

The Improving Landscape of HCV Therapy: The Opportunity to Eliminate a Scrouge

In recent years, significant progress has been made regarding the therapeutic options for chronic hepatitis C (CHC). This progress has the potential to significantly improve treatment success and tolerability rates; however, in order for that to occur, health care providers (HCPs) must be aware of the full range of treatment options currently available or in development. HCPs without this knowledge and ability have professional practice gaps that are likely to adversely affect CHC treatment outcomes.

This CME dinner series and related online program have been designed to address these practice gaps by updating clinicians on recent advances in CHC treatment, especially newer therapies. National thought leaders will lead participants through an overview of the current CHC treatment paradigms and present detailed clinical trial data on newly approved therapies and strategies and discuss products in development that are expected to shape treatment decisions in the near future. It is the goal of this program to address treatment gaps and provide clinicians with the tools needed to adjust their behavior so that they can provide optimal care to patients with CHC, thereby reducing morbidity and mortality associated with CHC.

Find out more »

Real Cases in HBV: Overcoming the Obstacles to Providing Care for Chronic Hepatitis B Patients

Real Cases in HBV: Overcoming the Obstacles to Providing Care for Chronic Hepatitis B Patients

National thought leaders lead this program using case-based panel discussions to drive home key messages regarding HBV diagnosis, monitoring and treatment while discussing barriers unique to different ethnic communities. Presenters will discuss transmission of HBV in various populations; symptoms of HBV infection; long-term risk and consequences of untreated HBV infection; major treatment guidelines for the diagnosis and management of patients with HBV infection; and the treatment of special populations of patients with HBV infection so that more patients can be screened or tested for HBV and receive the full benefit of available treatments for CHB, leading to decreased morbidity and mortality.

Course Directors:

Paul Kwo, MD
Associate Professor of Medicine,
Medical Director, Liver Transplantation
Division of Gastroenterology and Hepatology
Indiana University School of Medicine
Indianapolis, Indiana
Mark Sulkowski, MD
Associate Professor of Medicine,
Medical Director, Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Tram Tran, MD
Medical Director, Liver Transplantation
Cedars-Sinai Medical Center
Associate Professor,
University of California, Los Angeles
Los Angeles, California

Find out more »

Advances in Chronic Hepatitis C Management and Treatment

Advances in Chronic Hepatitis C Management and Treatment

CME programs from DDW.

 Watch on-demand CME symposium in English, Spanish, and French.

 Also includes CME newsletter.

Find out more »

First Annual Combination and Novel HCV Therapies Conference - CONO 2011

First Annual Combination and Novel HCV Therapies Conference - CONO 2011

Watch videos from important topics delivered by experts in HCV management at the recent CONO Conference, including:

- HCV epidemiology

- The use of HCV protease inhbitors

- New drugs in development

- The treatment of special populations

Conference Chairpersons:


Douglas T. Dieterich, MD
Professor of Medicine
Director of Outpatient Hepatology, Division of Liver Diseases
Director of CME, Department of Medicine,
Mount Sinai School of Medicine
New York, New York
Paul J. Pockros, MD
Head, Division of Gastroenterology/Hepatology
Director, SC Liver Research Consortium
The Scripps Clinic
La Jolla, California
Mark Sulkowski, MD
Associate Professor of Medicine and Medical Director,
Viral Hepatitis Center,
Johns Hopkins University School of Medicine
Baltimore, Maryland

Find out more »

The 47th Annual EASL: Online Expert Poster Review and Discussion

The 47th Annual EASL: Online Expert Poster Review and Discussion

Program Overview

This CME activity will feature four HCV experts reviewing and discussing the most important studies presented on chronic hepatitis C at EASL. This review and discussion will provide unique insight into how knowledgeable experts review the key posters and presentations at EASL and an in-depth understanding of the scientific quality and clinical relevance of the posters and presentations reviewed.

This program will enable all participating clinicians and health care providers caring for HCV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care.

Faculty

Douglas T. Dieterich, MD
Professor of Medicine and Director of CME,
Department of Medicine,
Director of Outpatient Hepatology,
Division of Liver Diseases,
Mount Sinai School of Medicine
New York, New York

Paul Y. Kwo, MD
Associate Professor of Medicine
Medical Director, Liver Transplantation
Division of Gastroenterology and Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Jürgen Rockstroh, MD
Professor
University of Bonn
Bonn, Germany

Paul J. Pockros, MD
Head, Division of Gastroenterology/Hepatology
Director, SC Liver Research Consortium
The Scripps Clinic
La Jolla, California

Find out more »

Advances in Chronic Hepatitis C Management and Treatment

Advances in Chronic Hepatitis C Management and Treatment

This 1.5 hour Internet symposium will review and discuss the key studies on chronic hepatitis C management and treatment presented at the 62nd AASLD. The symposium will feature 4 well-known and recognized thought leaders in the HCV field. This activity has been designed to meet the educational needs of physicians involved in the care of patients with chronic hepatitis C infection.

Course Director and Moderator

Mark Sulkowski, MD
Associate Professor of Medicine and Medical Director,
Viral Hepatitis Center,
Johns Hopkins University School of Medicine
Baltimore, Maryland

Faculty

Nezam H. Afdhal, MD
Associate Professor of Medicine,
Harvard School of Medicine
Chief of Hepatology, Director of Liver Center
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Fred Poordad, MD
Chief, Hepatology
Cedars-Sinai Medical Center
Associate Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

K. Rajender Reddy, MD
Professor of Medicine,
Director of Hepatology,
Medical Director of Liver Transplantation
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

Find out more »

Newer Treatments for HCV: What Every Clinician Should Know

Newer Treatments for HCV: What Every Clinician Should Know

Program Overview:

There has been significant recent progress in the management of patients with chronic hepatitis C (CHC), and cure rates continue to rise. However, before the millions of Americans with CHC can receive the full benefits of treatment, they must be diagnosed and appropriately treated. Physicians therefore need to learn how to identify those with CHC and provide optimal treatment for each patient, including an understanding of HCV genotypes, treatment schedules, drug-drug interactions, and the management of adverse effects, such as rash and anemia.


This live, two-hour long CME activity places an emphasis on updating treatment algorithms with new treatment options and reviewing new agents in development that impact treatment decisions made today.

Course Directors:

Mark Sulkowski, MD
Professor of Medicine
Medical Director, Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Paul Y. Kwo, MD
Professor of Medicine
Medical Director, Liver Transplantation
Division of Gastroenterology and Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Find out more »

Advances in HCV: New Challenges and Hope

Advances in HCV: New Challenges and Hope

Program Overview:

Over three million people in the United States have chronic HCV infection (CHC). CHC is the leading cause of cirrhosis and a common cause of hepatocellular carcinoma and liver transplantation. Fortunately, treatments exist that can often reduce the morbidity and mortality of CHC and the response rate to antiviral therapy is predicted to improve with the introduction of newer treatment options, including protease inhibitors, entry inhibitors and polymerase inhibitors. To improve patient outcomes, clinicians need to be aware of all treatment options and how to integrate them into current treatment algorithms. They also need to address problems with adherence to reduce the risk of resistance.

This online activity has been designed to focus on recent advances in CHC treatment, especially newer therapies. Three national thought leaders will lead viewers participants through an overview of the current CHC treatment paradigms and present detailed clinical trial data on newer therapies and strategies that are expected to shape treatment paradigms in the near future.

Faculty:

Bruce R. Bacon, MD
James F. King, MD Endowed Chair in Gastroenterology,
Professor of Internal Medicine
Saint Louis University School of Medicine
St. Louis, Missouri

Paul Y. Kwo, MD
Associate Professor of Medicine,
Medical Director,
Liver Transplantation Division of
Gastroenterology and Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Mark Sulkowski, MD
Associate Professor of Medicine and Medical Director,
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Find out more »

The 46th Annual EASL: Advances in Chronic Hepatitis C Management and Treatment

The 46th Annual EASL: Advances in Chronic Hepatitis C Management and Treatment

This 1.5-hour Internet symposium reviews and discusses the key studies on chronic hepatitis C management and treatment presented at EASL. The symposium will feature four well-known and recognized thought leaders in the HCV field, with three serving as presenting faculty/discussants and one as program moderator. This activity has been designed to meet the educational needs of physicians involved in the care of patients with chronic hepatitis C infection.

This program is certified for CME credit for US physicians by the Postgraduate Institute for Medicine.

 In addition to videos (available in French, English, and Spanish), the program offers poster reviews, slide presentations, and a CME newsletter. 

Course Director and Moderator

Mark Sulkowski, MD
Associate Professor of Medicine and Medical Director,
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Faculty

Nezam H. Afdhal, MD
Associate Professor of Medicine,
Harvard School of Medicine
Chief of Hepatology, Director of Liver Center,
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Fred Poordad, MD
Chief, Hepatology
Cedars-Sinai Medical Center
Associate Professor of Medicine,
David Geffen School of Medicine at UCLA
Los Angeles, California

K. Rajender Reddy, MD
Professor of Medicine,
Director of Hepatology,
Medical Director of Liver Transplantation
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

Find out more »

The 47th Annual EASL: Advances in Chronic Hepatitis C Management and Treatment

The 47th Annual EASL: Advances in Chronic Hepatitis C Management and Treatment

This Internet symposium will review and discuss the key studies on chronic hepatitis C management and treatment presented at EASL. The symposium will feature four well-known and recognized thought leaders in the HCV field, with three serving as presenting faculty/discussants and one as program moderator. 

This activity has been designed to meet the educational needs of physicians involved in the care of patients with chronic hepatitis C infection. This program is certified for CME credit for US physicians by the Postgraduate Institute for Medicine.

Course Director and Moderator

Mark Sulkowski, MD
Associate Professor of Medicine and Medical Director,
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Faculty

Nezam H. Afdhal, MD
Associate Professor of Medicine,
Harvard School of Medicine
Chief of Hepatology, Director of Liver Center,
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Fred Poordad, MD
Chief, Hepatology
Cedars-Sinai Medical Center
Associate Professor of Medicine,
David Geffen School of Medicine at UCLA
Los Angeles, California

K. Rajender Reddy, MD
Professor of Medicine,
Director of Hepatology,
Medical Director of Liver Transplantation
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania 

Find out more »